



## This Trading Floor Research report contains:

Biotechs Update

A Weekly Follow-up of Current Stock Positions

#### **Biotechs Update**

**Biotechs** were a group that remained strong during Friday's selloff that affected most sectors and industry groups. Even though most industry groups within the **healthcare sector** moved to sell signals, Biotech stocks moved fractionally higher.

Friday's strength opened the way for two biotech buy confirmations on Monday. I purchased **SenesTech (SNES)** and **Enlivex Therapeutics (ENLV).** 

Once **SenesTech (SNES)** confirmed it quickly shot up and hit three of its Fibonacci targets, and I sold 2/3's of my shares at the second and third targets, locking in 8.5% and 9.1% gains. SNES has been stair stepping up the right side of its base since April. Yesterday's confirmation started the next stair-step with substantial accumulation. Monday's powerful spread triple top breakout at 6.00 on the point & figure chart underscores the strong demand.

**Enlivex Therapeutics (ENLV)** is also stair-stepping the right side of its cup. The latest move has come with massive volume and is completing its cup-with-handle base. ENLV is experiencing some of the most substantial accumulation in the biotech group as accumulation hits the highest levels since October 2020. The 2020 robust build of accumulation sent ENLV 501% higher over the following five months.

Last week's biotech purchase of **HilleVax (HLVX)** was sold yesterday slightly below my purchase at 2.10. XOMA acquired HLVX, and a massive accumulation was picking up on traders' purchases before the event. However, the offer of 1.95 plus contingent value rights to shareholders was underwhelming and produced no price advance. I sold my shares and moved on to other biotech emerging leaders.





- The Themes Uranium & Nuclear ETF (URAN) was purchased on June 11 at 35.50. On July 17, I sold one-third of my position at its first Fibonacci target at 39.31, realizing an 8.8% gain. It closed at 38.86.
- Qudian (QD) was purchased on July 7 at 3.13. On July 30, I sold one-third of my position above its first Fibonacci target, realizing an 19.1% gain. On July 31, I sold another one-third of my position at its second Fibonacci target of 4.14, realizing an 32.3% gain. It closed at 3.96.
- FIGS Inc. (FIGS) was purchased on July 10 at 5.85. On July 22, I sold one-third of my position at its first Fibonacci target at 6.43, realizing a 9.9% gain. It closed at 6.17.



- One Stop Systems (OSS) was purchased on July 15 at 5.24. I sold one-third of my position at 5.66, realizing a 9.2% gain. It closed at 5.04.
- Altice USA (ATUS) was purchased on July 15 at 2.68. On July 18, I sold one-third of my position, approaching its first Fibonacci target at 2.95, and realized a 7.5% gain. It closed at 2.42.
- Dolly Varden Silver (DVS) was purchased on July 18 at 3.79. It closed at 3.51.



- Luxxfolio (LUXFF) was purchased on July 21 at .51. It closed at .398.
- ICZOOM (IZM) was purchased on July 29 at 2.58. It closed at 2.54.
- Enlivex Therapeutics (ENLV) was purchased on August 4 at 1.60. It closed at 1.39.



- SenesTech (SNES) was purchased on August 4 at 5.47. It closed at 5.36. On August 4, I sold one-third of my position at its second Fibonacci target, realizing an 8.5% gain. On August 4, I sold another one-third of my position at its Third Fibonacci target of 6.12, realizing an 9.1% gain. It closed at 5.36.
- The ProShares Ultra Short Dow 30 (DXD)was purchased on August 5 at 24.30. It closed at 24.37.


# Disclaimer

Before using this site, please make sure that you note the following important information:

# Do your Own Research

Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on our Website and wish to rely upon, whether for the purpose of making an investment decision or otherwise.

The content of this email is confidential and intended only for the recipient specified in the message. It is strictly forbidden to share any part of this message with any third party without the written consent of the sender. If you received this message by mistake, please reply to this message and follow with its deletion so that we can ensure such a mistake does not occur in the future.



The results are not (or may not be) representative of the performance of all selections made by the Trading Floor Research (TFR) newsletter.

We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only, and nothing herein constitutes investment, legal, accounting, or tax advice or a recommendation to buy, sell, or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors, or markets identified and described were or will be profitable. All information is current as of the date herein and is subject to change without notice.